OncoGenex's prostate cancer compound Custirsen gets fast track designation
Next generation gene sequencing from Athena Diagnostics streamlines epilepsy diagnosis
Acceleron and Celgene announce positive interim clinical data for sotatercept in end stage renal disease
Visit our sites for b2b sales and banking employees:
cafeb2bsales.com
cafebanking.com
Submit an article to cafepharma's CP Wire. Click here to find out more.
| Company | Average | Last 24 hrs |
Increase |
|---|---|---|---|
| Active Biotech | 2 | 30 | 1400 % |
| Cynapsus | 5 | 58 | 1060 % |
| Hyperion Therapeutics | 7 | 66 | 843 % |
| Athena Diagnostics | 1 | 9 | 800 % |
| Durect Corporation | 2 | 16 | 700 % |
| Durata Therapeutics | 2 | 12 | 500 % |
| Infinity Pharmaceuticals | 1 | 6 | 500 % |
| Array Biopharma | 5 | 29 | 480 % |
| NovaBay Pharmaceuticals | 3 | 17 | 467 % |
| CytRx | 10 | 54 | 440 % |